TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02713633

Intervention type: OTHER
Group type: OTHER
Intervention: internal Double-J stents
Description: internal stent, we use to approaches to insert it: 1- Retrograde by cystoscopy and this will take 10 minutes before starting the surgical procedure itself and we put the stent under fluoroscopy guidance and this is the commonest way we use now to put the internal stents. 2- ante grade, and this is basically inserting the stent during the surgical procedure itself from the kidney down to the ureter and this is done without fluoroscopy

Intervention type: OTHER
Group type: OTHER
Intervention: internal Double-J stents
Description: internal stent, we use to approaches to insert it: 1- Retrograde by cystoscopy and this will take 10 minutes before starting the surgical procedure itself and we put the stent under fluoroscopy guidance and this is the commonest way we use now to put the internal stents. 2- ante grade, and this is basically inserting the stent during the surgical procedure itself from the kidney down to the ureter and this is done without fluoroscopy

Intervention type: OTHER
Group type: OTHER
Intervention: External Stent
Description: we use one method, we choose were we will leave the stent and then we create a small hole in the kidney and then pull the stent through the hole and then create small hole in the abdominal fascia and then the skin, all this done under direct vision and control. So now the sent is outside the patient and connected directly to the kidney and the renal pelvis, then the distal part of the stent will be inserted across the anastomosis and before closing the renal pelvis (also under vision) toward the ureter. The external stent will be connected at the end of the procedure to a urine bag.

Intervention type: OTHER
Group type: OTHER
Intervention: External Stent
Description: we use one method, we choose were we will leave the stent and then we create a small hole in the kidney and then pull the stent through the hole and then create small hole in the abdominal fascia and then the skin, all this done under direct vision and control. So now the sent is outside the patient and connected directly to the kidney and the renal pelvis, then the distal part of the stent will be inserted across the anastomosis and before closing the renal pelvis (also under vision) toward the ureter. The external stent will be connected at the end of the procedure to a urine bag.
Study: NCT03400228

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The probiotic is composed of a combination of Lactobacillus acidophilus (LA-5®) and Bifidobacterium lactis (BB-12®).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin is a supplement feed based carbohydrate powder and tasteless.
Study: NCT01160029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nateglinide
Description: Nateglinide Tablets 120 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nateglinide
Description: Nateglinide Tablets 120 mg
Study: NCT03514875

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: MitoQ is a mitochondria-targeting antioxidant, which should improve NO bioavailability, and therefore vasodilation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: MitoQ is a mitochondria-targeting antioxidant, which should improve NO bioavailability, and therefore vasodilation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo will be used in a double blinded, randomized, cross-over design
Study: NCT02114736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tenotomy of the proximal rectus femoris tendon
Description: Surgical release of the proximal tendon of the rectus femoris

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin injection in the rectus femoris muscle
Description: Injections of 200U of Botox in the rectus femoris muscle with a 2ml/100U dilution
Study: NCT02924922

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic partial nephrectomy
Description: The renal hilus is identified and both vein and artery are dissected. A laparoscopic ultrasound probe is introduced through a 12 mm port to define the tumor resection margins. A laparoscopic Satinsky clamp is used to induce total kidney ischemia, clamping both vein and artery. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Ischemia is interrupted once renorrhaphy is completed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robot assisted partial nephrectomy
Description: The renal hilus is carefully dissected, so that the arterial segmental branches are reached. Tumor resection margins are identified through ultrasound. Drop-in bulldog clamps are used to clamp segmental arterial branches and induce selective ischemia. Indocyanine green 0.2-0.3mg/KG is infused intravenously a few seconds after the selective ischemia is induced. The Firefly near infra-red fluorescence system is used to determine the extent of the ischemic area. The ischemic zone can now be tailored to the tumor by adding or removing bulldog clamps according to the vascular anatomical conditions. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The resection defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Selective ischemia will be interrupted once renorrhaphy is completed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopic instruments
Description: Endoscope, Scissor, Needleholder, Forceps, Suction unit, Ports, Tissel, CO2, Sutures, Needles, Scalpel, Ultrasound-Probe, Monitors

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Da- Vinci Robot and conventional laparoscopic instruments
Description: Da Vinci Robot, Console, Ports and Instruments; Suction unit, Forceps, Tisseel, Ultrasound Probe, Monitors

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Study: NCT03463980

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion meditation (CM)
Description: CM session: 30 minute check-in regarding the participants' levels of suicidal ideation, as well as a discussion of current life stress and weekly meditation practice; a 30 minute didactic session that will describe the meditative technique introduced during the week; and a 30 minute guided meditation session. Participants are also encouraged to meditate at least 30 minutes a day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support group (SG)
Description: SG session: 90 minutes to talk about current concerns and to receive support and guidance from other group members and the leaders.
Study: NCT02204722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600mg/day of Imatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400mg/day of Imatinib
Study: NCT00174460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. Children randomized to the control group will get the possibility to continue treatment for a further year. The study will end after 2 and 3 years of observation, respectively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm
Description: Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. The study will end after 2 and 3 years of observation, respectively. Children randomized to the control group will get the possibility to continue treatment for a further year.
Study: NCT03514875

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo will be used in a double blinded, randomized, cross-over design
Study: NCT01273324

Intervention type: DEVICE
Intervention: ADM Cup
Description: ADM Cup
Study: NCT00915707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline
Description: Subjects are allowed time in bed for sleep as their usual time at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: Subjects sleep is reduced to 4.5 hours in bed for 4 nights.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Sleep Quality
Description: Subjects sleep quality is reduced for 4 nights.
Study: NCT03955991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: R-CBSM
Description: 10 weekly educational modules via an electronic tablet. A participant workbook is also provided that contains a summary of the rationale for each module, outline of each technique, and homework exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: R-CBSM
Description: 10 weekly educational modules via an electronic tablet. A participant workbook is also provided that contains a summary of the rationale for each module, outline of each technique, and homework exercises.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Standard of care Influenza vaccine for that given year.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Standard of care Influenza vaccine for that given year.
Study: NCT05397249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: The participants are given strategies of mindfulness, asked to complete worksheets and participate in meditations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: The participants are given strategies of mindfulness, asked to complete worksheets and participate in meditations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: The participants are given strategies of mindfulness, asked to complete worksheets and participate in meditations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: The participants are given strategies of mindfulness, asked to complete worksheets and participate in meditations.
Study: NCT00373178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosiglitazone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-diabetic medications
Study: NCT00891384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Patients will receive maintenance therapy according to their assigned treatment arm: 25 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Patients will receive maintenance therapy according to their assigned treatment arm:5 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression
Study: NCT03799939

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group
Description: Polyvinylidene fluoride mesh (Dynamesh IPST) is used on intraperitoneal onlay position to prevent parastomal hernia.
Study: NCT00320515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Phase 1 - dose escalating: 600 mg/m2 level 1, 700 mg/m2 level 2, 800 mg/m2 level 3, 900 mg/m2 level 4, intravenous (IV), every 21 days, until disease progression~Phase 2 - 700 mg/m2, intravenous (IV), every 21 days, until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2, intravenous (IV), every 21 days, until disease progression
Study: NCT04532905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training Exercises Therapy
Description: Five type of exercises: dumbbell bent row over, deadlift, lunge, shoulder press, and squat with each three sets and 10 repetitions. Between each set there will be 2-3 minute rest period and 8-10 minute rest period among each exercise type.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Strength Training Exercises Therapy
Description: Five type of exercises: dumbbell bent row over, deadlift, lunge, shoulder press, and squat with each three sets and 10 repetitions. Between each set there will be 2-3 minute rest period and 8-10 minute rest period among each exercise type.
Study: NCT00169156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40 mg/m2 D1 to D5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicine
Description: 50 mg/m2 D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1,4 mg/m2 D1
Study: NCT02870608

Intervention type: OTHER
Group type: OTHER
Intervention: lung and liver elastography measurement of fetus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lung and liver elastography measurement of fetus
Study: NCT03683953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells therapy
Description: mesenchymal stem cells treatement of BPD for safety and effect evaluation0.9% sodium chloride incontrol group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: 0.9% sodium chloride in control group
Study: NCT04638426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL237 tablet
Description: Treatment A : HL237 100mg, twice a day, Treatment B : HL237 200mg, twice a day, Treatment C : HL237 400mg, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL237 tablet
Description: Treatment A : HL237 100mg, twice a day, Treatment B : HL237 200mg, twice a day, Treatment C : HL237 400mg, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL237 tablet
Description: Treatment A : HL237 100mg, twice a day, Treatment B : HL237 200mg, twice a day, Treatment C : HL237 400mg, twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of HL237 tablet
Description: Placebo of HL237, twice a day
Study: NCT03922620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Local infiltration of 20cc of Liposomal Bupivacaine infiltrated to the surgical area

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Nerve Block
Description: Peripheral Nerve Block performed by anesthesia team (blocks will be given by same anesthesia provider utilizing same technique every time in order to reduce variations in delivery of peripheral nerve block).
Study: NCT03209856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D supplement will be given. Then, it will be maintained if pregnancy occurred
Study: NCT01709656

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: human mesenchymal stem cells,1\*10\^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment.~a total of 24 weeks for follow up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib, Celebrex®
Description: non-steroid anti-inflammatory drugs (NSAID):celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib, Celebrex®
Description: non-steroid anti-inflammatory drugs (NSAID):celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up
Study: NCT01481454

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine (split virion, inactivated)
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine (split virion, inactivated)
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine (split virion, inactivated)
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2011 to 2012 Trivalent Influenza Vaccine
Description: 0.5 mL, Intramuscular
Study: NCT00475189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: loestrin 24/4 vs loestrin 1/20
Description: One month of loestrin 1/20 then randomized to Loestrin 24/4 or Loestrin 1/20 x 3 months. After 3 months if randomized to 1/20 will be switched to 24/4 if already on 24/4 will be given a choice which OC they want to continue for 3 more months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: loestrin 1/20
Description: loestrin 1/20 1 tab 21/7 x 3mo and then changed to Loestrin 24 FE
Study: NCT01755871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: 0,5mg Fingolimod once a day
Study: NCT04177212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRZF111
Description: MRZF111 kit consisting of one syringe of RADIESSE® Volume injectable implant, injection needles and additional components. Physiological saline solution (0.9% NaCl) is used to dilute Radiesse Volume by 1:2. Radiesse consists of calcium hydroxylapatite particles suspended in an aqueous-based gel carrier.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRZF111
Description: MRZF111 kit consisting of one syringe of RADIESSE® Volume injectable implant, injection needles and additional components. Physiological saline solution (0.9% NaCl) is used to dilute Radiesse Volume by 1:2. Radiesse consists of calcium hydroxylapatite particles suspended in an aqueous-based gel carrier.
Study: NCT03893500

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home-based 6 minute walk test
Description: Participants will receive a loaner Apple Watch with the Walk.Talk.Track. (WTT, produced by PHaware) app downloaded. Participants will perform a daily 6MWT at home using the Apple Watch and WTT app. They will undergo a history and physical, blood draw, echocardiogram and in-clinic 6MWT at the baseline and 12-week follow up visit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-based 6 minute walk test
Description: Participants will receive a loaner Apple Watch with the Walk.Talk.Track. (WTT, produced by PHaware) app downloaded. Participants will perform a daily 6MWT at home using the Apple Watch and WTT app. They will undergo a history and physical, blood draw, echocardiogram and in-clinic 6MWT at the baseline and 12-week follow up visit.
Study: NCT01792115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E 200 IU/d
Description: Supplement-low dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E 400 IU/d
Description: Supplement-intermediate dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E 800 IU/d
Description: Supplement High Dose

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and Exercise
Description: Diet and Exercise for all Arms of the study at baseline

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and Exercise
Description: Diet and Exercise for all Arms of the study at baseline

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and Exercise
Description: Diet and Exercise for all Arms of the study at baseline
Study: NCT03469687

Intervention type: DEVICE
Group type: OTHER
Intervention: Symax uncemented hip stem
Study: NCT02865902

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low-Level Laser Therapy by Ezlase; Biolase®
Description: comparision of the effects of low-level-laser therapy on wound healing of palatal donor site

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy by Ezlase; Biolase®
Description: comparision of the effects of low-level-laser therapy on wound healing of palatal donor site
Study: NCT02658890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study: NCT03658824

Intervention type: OTHER
Group type: OTHER
Intervention: Behavioural Activation (BA)
Description: BA is based on the assumption that depression may be precipitated and is maintained by a reduction in healthy, adaptive behaviours and positive reinforcement of these, and an increase in avoidance behaviours. Together, these changes reduce the person's immediate distress, often at the expense of their medium and longer term goals. The therapy involves helping the individual to re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours that are constructive in the longer term.~The intervention consists of up to 20 individual therapy sessions of Behavioural Activation, with one booster session three months after the end of therapy. Each session lasts approximately 50 minutes and this is supplemented by home practice between sessions.

Intervention type: OTHER
Group type: OTHER
Intervention: Behavioural Activation (BA)
Description: BA is based on the assumption that depression may be precipitated and is maintained by a reduction in healthy, adaptive behaviours and positive reinforcement of these, and an increase in avoidance behaviours. Together, these changes reduce the person's immediate distress, often at the expense of their medium and longer term goals. The therapy involves helping the individual to re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours that are constructive in the longer term.~The intervention consists of up to 20 individual therapy sessions of Behavioural Activation, with one booster session three months after the end of therapy. Each session lasts approximately 50 minutes and this is supplemented by home practice between sessions.